Implications of Biomarker Testing in the Era of Targeted NSCLC Therapies (JA copy)

This module will present current and new clinical data of targeted therapies and how this information translates into personalized medicine and the development of individualized treatment plans for patients with NSCLC based on expression of biomarkers.

Using adaptive learning technology allows you to consume content at your own pace, reinforce areas where there are deficits in knowledge, and avoid topics where there is a level of expertise.

Target Audience

This program is designed to meet the educational needs of oncologists, pulmonologists, pathologists, interventional radiologists, physician assistants, nurses, pharmacists, and other health care professionals involved in the care of patients with NSCLC.

Learning Objectives

Following this activity, participants should be able to:

  • Identify actionable oncogenic mutations associated with NSCLC and their implications for diagnosis and treatment
Additional information

This activity is supported by an educational grant from Pfizer Inc.

Course summary
Available credit: 
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Course opens: 
Course expires: 

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest. In addition, all faculty presentations have been reviewed to ensure education is fair and balanced and that clinical content presented supports safe, effective patient care. Individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter.


NCCN continuing education considers financial relationships to create a conflict of interest when an individual has both a financial relationship with a commercial interest and the opportunity to affect continuing education content about the products or services of a commercial interest with which he/she has a financial relationship.

NCCN continuing education considers relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures

The faculty listed below discloses no relevant financial relationships:

Kasey Bamel, DNP
Grace Lin, MD

The faculty listed below discloses the following relevant financial relationships:

Matthew A. Gubens, MD, MS 
AstraZeneca Pharmaceuticals LP: Consulting Fee 
Celgene Corporation: Grant/Research Support 
Merck & Co., Inc.: Grant/Research Support 
Novartis Pharmaceuticals Corporation: Grant/Research Support
OncoMed Pharmaceuticals: Grant/Research Support 
Roche Laboratories, Inc./Genentech, Inc.: Grant/Research Support 
sanofi-aventis U.S.: Consulting Fee 
Trizell Ltd: Grant/Research Support 

David Ost, MD
Intuitive Surgical, Inc.: Grant/Research Support

Sandip P. Patel, MD
AstraZeneca Pharmaceuticals LP: Scientific Advisor 
AstraZeneca Pharmaceuticals LP/MedImmune Inc.: Grant/Research Support
Bristol-Myers Squibb Company: Grant/Research Support; Scientific Advisor  
Eli Lilly and Company: Grant/Research Support; Scientific Advisor 
Fate Therapeutics: Grant/Research Support
Genentech, Inc.: Scientific Advisor
Genocea Biosciences, Inc.: Grant/Research Support
Illumina, Inc.: Scientific Advisor
Incyte Corporation: Grant/Research Support
Iovance Biotherapeutics, Inc.: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
Paradigm Biopharmaceuticals Ltd: Scientific Advisor
Pfizer Inc.: Grant/Research Support
Rakuten Medical, Inc.: Scientific Advisor
Roche Laboratories, Inc./Genentech, Inc.: Grant/Research Support
Tempus Labs, Inc.: Scientific Advisor
Xcovery LLC: Grant/Research Support

Momen M. Wahidi, MD, MBA
Cook Medical LLC: Consulting Fee  
Olympus Corporation of the Americas: Consulting Fee
Pulmonx Corporation: Consulting Fee

Staff Disclosures

The Activity Planning staff listed below discloses no relevant financial relationships: 

NCCN: Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Karen Kanefield; Lisa Perfidio, MS; Kathy Ann Smith, CHCP
The France Foundation: Constance Kendros; Morghan Long; Heather Tarbox, MPH; Eve J. Wilson, PhD, CHCP, ELS

The NCCN Clinical staff listed below discloses no relevant financial relationships:

Miranda Hughes, PhD

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NCCN designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCN designates this educational activity for a maximum of 0.75 contact hour.

NCCN designates this knowledge-based continuing education activity for 0.75 contact hour (0.075 CEUs) of continuing education credit. UAN: JA4008196-0000-21-041-H01-P

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit. Approval is valid until May 6, 2022. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing